Annals of Oncology 8:155-162, 1997
© 1997 European Society for Medical Oncology
research-article |
Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer*
1Hadassah Medical Centre Ein Karem Jerusalem, Israel
2Pharmacia and Upjohn S.p.A. Milan, Italy
3Insitutal Oncologic Cluj, Rumania
4 Current address. Ciba-Geigy Basel, Switzerland
5Ospedale St Orsola-Malpighi Bologna, Italy
6Scientific Centre of Oncology Academy of Medical Science Moscow, Russia
7Praca Amadeu Amaral Sao Paulo, Brasil
8University of Wien Wien, Austria
Correspondence to: E. Colajori, MD Pharmacia & Upjohn S.p.A. Via Robert Koch 1.2 20152 Milan Italy
PURPOSE:: A phase III study was performed in patients with metastatic breast cancer (MBC) to evaluate the effect on response rate and survival of a doubling of the epirubicin dose intensity.
PATIENTS AND METHODS:: Four hundred fifty-six patients were randomised to receive either epirubicin 100 mg/m2 or 50 mg/m2 in combination with 5-FU (500 mg/m2) and cyclophosphamide (500 mg/m2) (FEC 100 vs. FEC 50) i.v., every 21 days for a maximum of six cycles (eight in case of CR).
RESULTS:: Of 456 patients, 390 were evaluable for efficacy. Objective response (CR + PR) was seen in 57% (FEC 100) vs. 41% (FEC 50) of the evaluable patients (P = 0.003). The CR rate was higher in the FEC 100 arm (12% vs. 7%, P = 0.07). FEC 100 produced significantly higher response rates in patients with visceral localisation (50% vs. 34%, P = 0.011) and in patients with more than two metastatic organ sites (64% vs. 37%, P = 0.001). Median time to progression (7.6 vs. 7 months) and overall survival (18 months vs. 17 months) were similar. Myelosuppression was the principal toxic effect, with grade IV neutropenia observed in 57% of the patients treated with FEC 100 vs. 9% of those on FEC 50. Grade IV infection or febrile neutropenia were observed in 8% (FEC 100) vs. 0.4% (FEC 50), but the incidence of septic death was the same in the two arms (two patients each). Cardiac toxicity was similar in the two treatment groups, with 5% vs. 3% of the patients taken off study due to cardiac events, primarily due to a decline in LVEF. Only three patients (two in FEC 100) experienced congestive heart failure.
CONCLUSION:: This trial shows that FEC with epirubicin at 100 mg/m2 can be administered for repeated cycles without bone marrow support with increased, though acceptable, toxicity and with a significant increase of antitumor effect (especially in visceral and/or high-burden disease), but no increased survival.
dose intensification, epirubicin, metastatic breast cancer
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J.-U. Blohmer, P. Schmid, J. Hilfrich, K. Friese, A. Kleine-Tebbe, H. Koelbl, H. Sommer, G. Morack, M. B. Wischnewsky, W. Lichtenegger, et al. Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial Ann. Onc., January 20, 2010; (2010) mdp585v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mauri, N. P. Polyzos, G. Salanti, N. Pavlidis, and J. P. A. Ioannidis Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer J Natl Cancer Inst, December 17, 2008; 100(24): 1780 - 1791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bruzzi, L. Del Mastro, M. P. Sormani, L. Bastholt, M. Danova, C. Focan, G. Fountzilas, J. Paul, R. Rosso, and M. Venturini Objective Response to Chemotherapy As a Potential Surrogate End Point of Survival in Metastatic Breast Cancer Patients J. Clin. Oncol., August 1, 2005; 23(22): 5117 - 5125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Ejlertsen, H. T. Mouridsen, S. T. Langkjer, J. Andersen, J. Sjostrom, and M. Kjaer Phase III Study of Intravenous Vinorelbine in Combination With Epirubicin Versus Epirubicin Alone in Patients With Advanced Breast Cancer: A Scandinavian Breast Group Trial (SBG9403) J. Clin. Oncol., June 15, 2004; 22(12): 2313 - 2320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Baldini, G. Gardin, P. G. Giannessi, G. Evangelista, M. Roncella, T. Prochilo, P. Collecchi, R. Rosso, R. Lionetto, P. Bruzzi, et al. Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer Ann. Onc., February 1, 2003; 14(2): 227 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Heidemann, H. Stoeger, R. Souchon, W.-D. Hirschmann, H. Bodenstein, C. Oberhoff, J. T. Fischer, M. Schulze, M. Clemens, R. Andreesen, et al. Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial Ann. Onc., November 1, 2002; 13(11): 1717 - 1729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Michaud and K. L. Jones Recent Advances in the Systemic Management of Metastatic Breast Cancer Journal of Pharmacy Practice, February 1, 2002; 15(1): 52 - 61. [Abstract] [PDF]
|
|
|
|
|
|
L. Del Mastro, M. Venturini, R. Lionetto, F. Carnino, D. Guarneri, L. Gallo, A. Contu, P. Pronzato, L. Vesentini, M. Bergaglio, et al. Accelerated-Intensified Cyclophosphamide, Epirubicin, and Fluorouracil (CEF) Compared With Standard CEF in Metastatic Breast Cancer Patients: Results of a Multicenter, Randomized Phase III Study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group J. Clin. Oncol., April 15, 2001; 19(8): 2213 - 2221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Ackland, A. Anton, G. P. Breitbach, E. Colajori, J. M. Tursi, C. Delfino, A. Efremidis, A. Ezzat, A. Fittipaldo, K. Kolaric, et al. Dose-Intensive Epirubicin-Based Chemotherapy Is Superior to an Intensive Intravenous Cyclophosphamide, Methotrexate, and Fluorouracil Regimen in Metastatic Breast Cancer: A Randomized Multinational Study J. Clin. Oncol., February 15, 2001; 19(4): 943 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Benefit of a High-Dose Epirubicin Regimen in Adjuvant Chemotherapy for Node-Positive Breast Cancer Patients With Poor Prognostic Factors: 5-Year Follow-Up Results of French Adjuvant Study Group 05 Randomized Trial J. Clin. Oncol., February 1, 2001; 19(3): 602 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Epirubicin-Based Chemotherapy in Metastatic Breast Cancer Patients: Role of Dose-Intensity and Duration of Treatment J. Clin. Oncol., September 17, 2000; 18(17): 3115 - 3124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. W. Hu, G. D. Long, K. E. Stockerl-Goldstein, L. J. Johnston, N. J. Chao, R. S. Negrin, and K. G. Blume A Feasibility Study of Multiple Cycle Therapy with Melphalan, Thiotepa, and Paclitaxel followed by Mitoxantrone, Thiotepa, and Paclitaxel with Autologous Hematopoietic Cell Support for Metastatic Breast Cancer Clin. Cancer Res., November 1, 1999; 5(11): 3411 - 3418. [Abstract] [Full Text] [PDF]
|
|